Last updated: August 1, 2026
Zestoretic is the fixed-dose combination of lisinopril and hydrochlorothiazide used to treat hypertension. Its clinical development is complete, its active ingredients are available from multiple generic manufacturers, and no meaningful branded exclusivity remains. The commercial outlook is therefore driven by generic prescription volume, reimbursement, pharmacy contracting and low-cost competition rather than new clinical-trial data.
The combination remains clinically relevant because it pairs an angiotensin-converting enzyme inhibitor with a thiazide diuretic. Its market position is weaker than that of newer fixed-dose combinations because lisinopril/hydrochlorothiazide is inexpensive, therapeutically substitutable and exposed to extensive generic competition.
What is Zestoretic and how does it work?
Zestoretic contains lisinopril and hydrochlorothiazide in a single oral tablet.
| Attribute |
Zestoretic |
| Active ingredients |
Lisinopril and hydrochlorothiazide |
| Drug class |
ACE inhibitor plus thiazide diuretic |
| Primary indication |
Hypertension |
| Dosage forms |
Oral tablets |
| Common strengths |
10/12.5 mg, 20/12.5 mg, 20/25 mg |
| Original developer |
AstraZeneca |
| Reference product status |
Legacy branded product |
| Generic status |
Broadly available |
| Biologic status |
Not applicable |
| FDA pathway for generics |
Abbreviated New Drug Application, or ANDA |
| Principal clinical risks |
Hyperkalemia, renal impairment, hypotension, cough, angioedema and electrolyte abnormalities |
Lisinopril inhibits formation of angiotensin II, reducing vasoconstriction and aldosterone activity. Hydrochlorothiazide increases urinary sodium and fluid excretion. The combination lowers blood pressure through complementary mechanisms.
Zestoretic is not indicated for acute blood-pressure reduction. It is generally used when monotherapy does not provide adequate control or when patients are switched from separate lisinopril and hydrochlorothiazide tablets.
What clinical trials support Zestoretic?
Zestoretic was supported by the established antihypertensive efficacy of its two components and by clinical studies evaluating the combination across patients whose blood pressure was not adequately controlled with either component alone.
The product label reports dose-related reductions in blood pressure and describes the combination as providing additive antihypertensive activity. The original clinical program predates the modern ClinicalTrials.gov registration framework, so many foundational studies are not represented as contemporary registered trials in the same way as newer products (U.S. Food and Drug Administration, 2024a).
What is the current Zestoretic clinical-trial status?
No active late-stage development program is associated with Zestoretic. The product is a mature antihypertensive combination with established efficacy, safety and dosing information.
ClinicalTrials.gov records may include studies of:
- Lisinopril alone
- Hydrochlorothiazide alone
- ACE inhibitor and diuretic combinations
- Hypertension treatment strategies
- Cardiovascular outcomes involving background antihypertensive therapy
Those studies should not be treated as new Zestoretic registration trials unless they specifically identify the fixed-dose product or its exact formulation (National Library of Medicine, 2025).
| Trial category |
Current relevance to Zestoretic |
| New pivotal efficacy trials |
No active program identified |
| Confirmatory Phase 3 studies |
Not expected for this legacy product |
| Pediatric development |
No current branded program |
| Cardiovascular-outcome trials |
Generally component- or class-based rather than Zestoretic-specific |
| Postmarketing safety |
Routine pharmacovigilance and label-based monitoring |
| Reformulation studies |
No material branded development activity identified |
The principal clinical evidence base now comes from historical trials, FDA labeling, hypertension guidelines and real-world use of the individual ingredients.
What is the FDA regulatory status of Zestoretic?
Zestoretic is an FDA-approved prescription antihypertensive. The reference product is supported by an FDA-approved labeling package covering indications, contraindications, warnings, dosing and adverse reactions (U.S. Food and Drug Administration, 2024a).
Important label restrictions include:
- Pregnancy is a major contraindication because ACE inhibitors can cause fetal injury or death.
- Patients with prior ACE-inhibitor-associated angioedema should not receive lisinopril.
- Concomitant aliskiren use is contraindicated in patients with diabetes.
- Renal function and potassium should be monitored.
- The drug should not be used with sacubitril/valsartan within the specified separation period because of angioedema risk.
- Lithium exposure can increase with ACE inhibitor and diuretic therapy.
Hydrochlorothiazide also creates risks of hyponatremia, hypokalemia, hyperuricemia, photosensitivity and glucose intolerance. The combination is most commercially relevant for patients who need two-drug blood-pressure treatment in one tablet.
What patents protect Zestoretic?
No material unexpired composition-of-matter patent is expected to protect Zestoretic in the United States. The product contains two long-established small-molecule active ingredients, and generic versions have been marketed for many years.
| IP category |
Zestoretic position |
| Composition-of-matter patent |
Expired or commercially irrelevant |
| Original formulation patents |
Expired or commercially irrelevant |
| Method-of-use patents |
No meaningful current barrier identified |
| Orange Book exclusivity |
No current branded exclusivity expected |
| Generic substitution |
Broadly permitted under state and payer rules |
| Manufacturing barriers |
Low for qualified tablet manufacturers |
| Patent litigation risk |
Low compared with newly launched branded drugs |
The relevant competitive issue is abbreviated approval, not patent enforcement. Generic manufacturers can rely on the reference product’s safety and efficacy findings and demonstrate pharmaceutical equivalence and bioequivalence through the ANDA pathway.
What is the Orange Book status of Zestoretic?
The FDA Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. Zestoretic’s commercial exposure is consistent with a legacy product whose principal patent and regulatory exclusivity periods have elapsed (U.S. Food and Drug Administration, 2024b).
A current Orange Book review should distinguish:
- The historical branded reference product.
- Authorized or legacy brand listings.
- Generic lisinopril/hydrochlorothiazide ANDAs.
- Any listing that remains administratively active without creating meaningful market exclusivity.
A listing alone does not establish durable commercial protection. For Zestoretic, the practical market result is generic competition rather than a patent-constrained market.
When did Zestoretic lose exclusivity?
Zestoretic lost meaningful market exclusivity years ago. Generic lisinopril/hydrochlorothiazide products have been available for an extended period, and the combination now competes primarily as a low-cost generic.
The original brand’s commercial protection ended through the combined effect of:
- Expiration of historical patent rights.
- Completion of FDA regulatory exclusivity.
- Approval of multiple ANDA products.
- Substitution by pharmacies and health plans.
- Availability of lisinopril and hydrochlorothiazide as separate low-cost tablets.
No credible generic launch event comparable to a first Paragraph IV entry is expected for the legacy Zestoretic product. Any current ANDA activity would normally relate to manufacturing, labeling, supplier status or market-share changes rather than the opening of a protected brand market.
Which companies compete with Zestoretic?
Competition comes from generic manufacturers and from alternative fixed-dose antihypertensive combinations.
Potential suppliers of lisinopril/hydrochlorothiazide or comparable products include large generic manufacturers such as:
- Teva Pharmaceutical Industries
- Viatris
- Sandoz
- Lupin
- Aurobindo Pharma
- Dr. Reddy’s Laboratories
- Torrent Pharmaceuticals
- Solco Healthcare
- Rising Pharmaceuticals
- Various contract and regional suppliers
The exact active supplier set changes as manufacturers enter, exit or suspend products. FDA approval does not guarantee continuous commercial distribution.
How does Zestoretic compare with competing antihypertensive combinations?
| Combination |
Commercial position |
Clinical differentiation |
| Lisinopril/hydrochlorothiazide |
Mature, low-cost generic |
Familiar ACE inhibitor plus thiazide |
| Losartan/hydrochlorothiazide |
Mature generic |
ARB option, often used when ACE-inhibitor cough occurs |
| Amlodipine/benazepril |
Generic fixed-dose combination |
Calcium-channel blocker plus ACE inhibitor |
| Amlodipine/valsartan |
Generic or branded depending on product |
Calcium-channel blocker plus ARB |
| Irbesartan/hydrochlorothiazide |
Generic |
ARB plus thiazide |
| Olmesartan/hydrochlorothiazide |
Generic |
ARB plus thiazide |
| Separate lisinopril and hydrochlorothiazide tablets |
Very low-cost substitute |
Allows independent dose titration |
Zestoretic has a cost advantage but limited differentiation. ARB-based combinations can capture patients who develop cough or intolerance on ACE inhibitors. Amlodipine-based combinations may be preferred when clinicians prioritize calcium-channel-blocker therapy.
What is the market size and forecast for Zestoretic?
Zestoretic-specific revenue is no longer a meaningful standalone branded-market category. The relevant market is the U.S. and global generic lisinopril/hydrochlorothiazide segment.
Public market databases often group the product with broader antihypertensive categories, making drug-specific revenue estimates difficult to isolate. A practical forecast should therefore separate branded revenue, generic product revenue and total treated-patient demand.
Analyst market projection
| Metric |
2024 estimate |
2025-2029 outlook |
| Branded Zestoretic revenue |
De minimis |
Continued decline or discontinuation |
| Generic unit demand |
Stable to modestly rising |
Approximately 1%-3% annual volume growth |
| Average generic selling price |
Low |
Approximately 2%-6% annual erosion |
| Nominal market value |
Flat to declining |
Approximately 1%-4% annual decline |
| Prescription demand driver |
Hypertension prevalence and treatment |
Aging population, combination therapy and adherence |
| Primary downside |
Price competition and supplier exits |
Further price erosion and substitution |
The volume outlook is stronger than the value outlook. Hypertension prevalence supports persistent demand, while generic price competition limits revenue growth. Under a midpoint scenario, unit demand increases about 10% to 16% cumulatively from 2025 through 2029, while market value declines about 5% to 18% because of price erosion.
This is a mature-generic forecast rather than a branded-growth forecast. It assumes no meaningful reformulation, new indication, authorized-brand relaunch or supply disruption.
What revenue exposure does Zestoretic create for manufacturers?
Zestoretic has low revenue concentration risk for diversified generic companies because the product is inexpensive and interchangeable. Its value lies in portfolio breadth, manufacturing utilization and pharmacy-contracting volume.
Revenue exposure is highest for manufacturers that:
- Maintain a large hypertension portfolio.
- Supply major retail pharmacy chains.
- Compete for low-price preferred formulary positions.
- Produce the individual lisinopril and hydrochlorothiazide tablets.
- Have low-cost manufacturing in India or other competitive production regions.
The product is unlikely to support premium pricing. A manufacturer that loses supply may lose prescriptions rapidly to another approved generic supplier.
What manufacturing and intellectual-property barriers affect Zestoretic?
Manufacturing barriers are limited but not zero. The active ingredients are established, and tablet production is technically routine. Commercial barriers include:
- Consistent API supply.
- Control of hydrochlorothiazide content uniformity.
- Stability and dissolution performance.
- Bioequivalence requirements.
- FDA manufacturing compliance.
- Reliable packaging and distribution.
- Ability to sustain low prices without supply interruptions.
Because the product is a fixed-dose combination, manufacturers must demonstrate that both active ingredients meet applicable quality and bioequivalence requirements. These obligations create operational barriers but do not create durable exclusivity.
What generic launch risks exist for Zestoretic?
Generic launch risk is low from an innovator perspective and moderate from a supplier perspective.
Innovator-side risk
- No significant remaining patent barrier.
- No meaningful Paragraph IV litigation opportunity.
- No premium-price defense.
- High substitution pressure.
- Limited ability to differentiate the legacy brand.
Generic-supplier risk
- Rapid price compression after new entry.
- Low switching costs for pharmacies.
- Contract losses when a competitor offers lower pricing.
- FDA inspection or manufacturing interruption.
- API shortages.
- Product discontinuation if margins become uneconomic.
A new supplier could enter a market with persistent demand but still generate limited returns because several established manufacturers already compete on price.
What patent litigation and settlements affect Zestoretic?
No major current patent litigation or settlement is expected to determine Zestoretic market access. Historical generic approvals may have involved routine patent certifications, but those events no longer define the product’s competitive position.
The legal environment is materially different from that of a protected combination product with active Orange Book patents. For Zestoretic, the key legal questions concern product liability, manufacturing compliance, labeling and supply contracts rather than Paragraph IV litigation.
What is the competitive outlook for Zestoretic through 2029?
Zestoretic should remain commercially durable as a low-cost generic combination, but it is unlikely to produce branded growth.
The most probable outlook is:
- Stable or modestly increasing patient demand.
- Continued migration from the Zestoretic brand to generic equivalents.
- Ongoing substitution by losartan/hydrochlorothiazide and other ARB combinations.
- Persistent use of separate lisinopril and hydrochlorothiazide tablets where dose flexibility matters.
- Declining average selling prices.
- Limited clinical-trial or lifecycle-management activity.
- Low patent-driven market disruption.
Key Takeaways
- Zestoretic is the lisinopril/hydrochlorothiazide fixed-dose combination for hypertension.
- Its clinical development is complete, with no meaningful active branded trial program.
- FDA approval and labeling remain relevant, but regulatory exclusivity has expired.
- No material unexpired patent estate is expected to restrict generic competition.
- The market is driven by generic volume, pharmacy contracting and reimbursement.
- Generic demand should remain stable to modestly higher through 2029.
- Market value is likely to decline because price erosion will exceed volume growth.
- Paragraph IV litigation and settlement risk are low.
- The main competitive threats are ARB/thiazide combinations and separate-component prescribing.
- Manufacturing reliability, API supply and low-cost production are more important than intellectual property.
FAQs About Zestoretic Clinical Trials, Patents and Market Forecasts
Is Zestoretic still sold under the original brand name?
Generic lisinopril/hydrochlorothiazide products are widely available. The original brand has limited commercial relevance compared with generic equivalents.
Is there a generic version of Zestoretic?
Yes. Generic versions contain lisinopril and hydrochlorothiazide in the same fixed-dose combinations and are approved through the FDA ANDA pathway.
Can Zestoretic be replaced by separate lisinopril and hydrochlorothiazide tablets?
Yes, clinicians can prescribe the two components separately when dose flexibility, formulary coverage or supply availability makes that approach preferable.
Is Zestoretic safer than losartan/hydrochlorothiazide?
Neither combination is universally safer. Lisinopril can cause cough and angioedema, while losartan generally has a lower cough risk. Both combinations require attention to renal function, potassium and blood pressure.
Does Zestoretic have biosimilar competition?
No. Zestoretic is a small-molecule drug, not a biologic. Its competitors are generic drugs approved through ANDAs, not biosimilars.
References
-
National Library of Medicine. (2025). ClinicalTrials.gov. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (2024a). Zestoretic (lisinopril and hydrochlorothiazide) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (2024c). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
